1.A study of cold agglutinin titer in schizophrenia.
Dong In KIM ; Ik Keun HWANG ; Yim KIM
Journal of Korean Neuropsychiatric Association 1993;32(3):326-333
No abstract available.
Schizophrenia*
2.Treatment Response, Remission and Recovery in Schizophrenia: Definition and Criteria.
Young Chul CHUNG ; Gwang Hyun CHO ; Tae Won PARK
Korean Journal of Psychopharmacology 2006;17(1):5-12
Understanding the definition of treatment response, remission and recovery is very critical in terms of investigating the course of schizophrenia and planning treatment strategies accordingly. In this article, we reviewed various definitions and criteria used in previous studies. Based on this, several limitations and new proposals are discussed. Clear establishment of the criteria for treatment response, remission and recovery for schizophrenia would help clinicians to make a time-appropriate decision for medication plan and to set up the long-term treatment goal in people with schizophrenia.
Schizophrenia*
3.The study on the attention disorder of schizophrenia by the stroop color word test.
Sang Lyeoul LEE ; Sang Woo OH ; Kuy Haeng LEE
Journal of Korean Neuropsychiatric Association 1991;30(1):98-111
No abstract available.
Schizophrenia*
4.Therapeutic effects of resperidone in the treatment of chronic schizophrenia.
Soon Won PARK ; Hae Ik CHUNG ; Byung Jo KANG
Journal of Korean Neuropsychiatric Association 1993;32(5):744-757
No abstract available.
Schizophrenia*
5.A retropective study on late onset schizophrenia.
Hyun Sang HONG ; Young Lae CHAE ; In Ho PAIK
Journal of Korean Neuropsychiatric Association 1991;30(6):990-995
No abstract available.
Schizophrenia*
6.The relationship between simple attention and clinical symptoms in schizophrenia.
Journal of Korean Neuropsychiatric Association 1992;31(2):252-257
No abstract available.
Schizophrenia*
7.Schizophrenia and Immunological Abnormalities.
Journal of the Korean Society of Biological Psychiatry 2008;15(3):152-174
There have been vast amount studies regarding immunologic dysregulation in schizophrenia. The mechanism of immune pathogenesis in schizophrenia still is unclear, even though various immune dysfunction have been reported. We endeavored to report on two major hypothesis on immunologic dysregulation in schizophrenia, the infection hypothesis and autoimmune hypothesis. We went on to focus on the autoimmune hypothesis, which has received the most attention over the years. We explored the accumulated data and the rational behind the autoimmune hypothesis and the implications of the autoimmune hypothesis for future research in the pathogenesis of schizophrenia
Schizophrenia
8.Managing ‘Schizophrenia in the Midst of Schizophrenia’- The Role of Assertive Community Treatment
Ahmad Nabil MR ; Marhani M ; Azlin B
Medicine and Health 2014;9(2):139-142
This case report emphasizes the role of Assertive Community Treatment (ACT)in managing a family with four members suffering from mental illness, mainly schizophrenia. We report a case of middle-aged lady who was diagnosed with treatment resistant schizophrenia (TRS) living with two other family members with the same illness and their carer who developed major depression from shouldering the burden of caring for mentally ill family members. ACT, through its holistic approach, proved to have reduced hospitalizations and improve symptom control
and quality of life in this family.
Schizophrenia
10.Estimated range of cost of treatment of adult Schizophrenia patients at a tertiary government hospital as of October 2015
Anthony T. Abala ; Tomas Bautista
The Philippine Journal of Psychiatry 2021;2(1-2):32-47
OBJECTIVES:
Using the patient’s perspective, the study’s objective was to estimate the economic cost of treatment for adult schizophrenia patients in a tertiary hospital using key informant interviews.
METHODS:
A guided structured key informant interview was done to determine key practices in the treatment of adult schizophrenic patients in the charity and pay in-patient and out-patient settings of the tertiary hospital. Cost of treatment included direct (medication, room and board, professional fees, ancillaries) and indirect costs (productivity losses of both patient and caregiver) and was computed based on 1 to 4 week length of stay for inpatients and varying intervals of follow-up for outpatients. Total costs were computed depending on the treatment setting.
RESULTS:
Twenty nine members of the Department of Psychiatry, involving 5 psychiatric nursing staff, 13 residents-in-training, 4 fellows-in-training and 7 consultants were interviewed. The cost, for charity inpatient care, may range from PhP 2332.00 to PhP 44,861.00 (USD 50.88 to 978.86). For charity outpatient care, this may range from PhP 2892.00 to PhP 21,3612.00 (USD 63.10 to 4660.96) annually. For pay patients, costs were estimated to range from PhP15347.00 to PhP 24,6831.00 (USD 334.87 to 5385.80) for inpatient care and PhP 17,292.00 to PhP 1,125,600.00 (USD 377.31 to 25681.04) for outpatient care. The factor that influenced costs the most was the choice of medication. As of October 15, 2015, 1 USD = 45.83 PhP.
CONCLUSION
Schizophrenia is a chronic psychiatric illness that places a significant financial burden on patients and their caregivers. Based on the data gathered, patients’ and their families could spend from as low as 2332 to as high as 1,125,600 pesos depending on the treatment setting.
Schizophrenia